Gonnade Nitesh, Lokhande Vaibhav, Ajij Mohammed, Gaur Anil, Shukla Kamalakant
Assistant Professor in Physical Medicine and Rehabilitation, All India Institute of Medical sciences, Jodhpur, Rajasthan, India.
Senior resident in Physical Medicine and Rehabilitation, All India Institute of Medical Sciences, Jodhpur, Rajasthan, India.
J Pediatr Neurosci. 2017 Oct-Dec;12(4):338-343. doi: 10.4103/jpn.JPN_123_17.
The aim of this study is to compare the treatment effectiveness of botulinum toxin type A (BTX-A) and phenol blocks in the management of lower limb spasticity and to measure improvement in gross motor functional outcome in children with cerebral palsy (CP). This is a hospital-based prospective, noncontrolled randomized study that took place in a tertiary care center. A total of 61 ambulatory children with CP spastic diplegia, aged from 4 to 10 years, were randomly divided into two groups and included in this study. Twenty-eight children with CP received BTX-A injections and 33 received phenol motor point blocks. The measures performed were as follows: outcome assessment spasticity by the Modified Ashworth scale (MAS), active range of motion (AROM) of lower limb joint by goniometer, and functional improvement by Gross Motor Function Measures (GMFM). Postinjection follow-up done at 2, 6, 12, 24, and 48 weeks. Significant improvement in reduction of spasticity, increased AROM of all joints of lower limbs, and improvement in functional outcome were observed in CP with spastic diplegia after BTX-A injections as compared with the phenol motor point block group. There was no significant side effect after BTX-A injections as compared with phenol injections. BTX-A injections showed superior treatment effects in the reduction of spasticity and improvement in AROM and functional outcome measures with spastic diplegia as compared with phenol blocks. BTX-A injections also revealed fewer clinical side effects and were well tolerated by children with CP.
本研究的目的是比较A型肉毒毒素(BTX-A)和苯酚阻滞在治疗下肢痉挛方面的效果,并测量脑瘫(CP)患儿粗大运动功能结果的改善情况。这是一项在三级医疗中心进行的基于医院的前瞻性、非对照随机研究。共有61名年龄在4至10岁之间、患有痉挛性双侧瘫的CP门诊患儿被随机分为两组并纳入本研究。28名CP患儿接受了BTX-A注射,33名接受了苯酚运动点阻滞。所进行的测量如下:采用改良Ashworth量表(MAS)评估痉挛结果,用角度计测量下肢关节的主动活动范围(AROM),并用粗大运动功能测量(GMFM)评估功能改善情况。注射后在2周、6周、12周、24周和48周进行随访。与苯酚运动点阻滞组相比,BTX-A注射后,痉挛性双侧瘫的CP患儿在痉挛减轻、下肢所有关节的AROM增加以及功能结果改善方面有显著改善。与苯酚注射相比,BTX-A注射后没有明显的副作用。与苯酚阻滞相比,BTX-A注射在减轻痉挛、改善AROM和痉挛性双侧瘫的功能结果测量方面显示出更好的治疗效果。BTX-A注射还显示出较少的临床副作用,并且CP患儿耐受性良好。